ECSP18015616A - Tableta - Google Patents

Tableta

Info

Publication number
ECSP18015616A
ECSP18015616A ECIEPI201815616A ECPI201815616A ECSP18015616A EC SP18015616 A ECSP18015616 A EC SP18015616A EC IEPI201815616 A ECIEPI201815616 A EC IEPI201815616A EC PI201815616 A ECPI201815616 A EC PI201815616A EC SP18015616 A ECSP18015616 A EC SP18015616A
Authority
EC
Ecuador
Prior art keywords
tablet
acid
competitive
outer layer
active ingredients
Prior art date
Application number
ECIEPI201815616A
Other languages
English (en)
Inventor
Yoshihiro Uchiyama
Arisa Maeda
Yuichi Sugiyama
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of ECSP18015616A publication Critical patent/ECSP18015616A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona una tableta en la cual la estabilidad de los ingredientes activos (un bloqueador de ácido competitivo con el ion de potasio y ácido acetilsalicílico) es alta y las actividades farmacológicas de los ingredientes activos se pueden ejercer de manera estable y rápida después de la administración de la tableta. La presente invención se refiere a una tableta con revestimiento entérico que tiene un núcleo interior y una capa exterior, en donde el núcleo interior contiene ácido acetilsalicílico y la capa exterior contiene un bloqueador de ácido competitivo con el ion de potasio que no está revestido entéricamente.
ECIEPI201815616A 2015-07-30 2018-02-28 Tableta ECSP18015616A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015151336 2015-07-30

Publications (1)

Publication Number Publication Date
ECSP18015616A true ECSP18015616A (es) 2018-07-31

Family

ID=57884505

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201815616A ECSP18015616A (es) 2015-07-30 2018-02-28 Tableta

Country Status (20)

Country Link
US (1) US10835541B2 (es)
EP (1) EP3329921B1 (es)
JP (1) JP6778680B2 (es)
KR (1) KR102923965B1 (es)
CN (1) CN108135915B (es)
BR (1) BR112018001859B1 (es)
CA (1) CA2994073C (es)
CL (1) CL2018000246A1 (es)
CO (1) CO2018000991A2 (es)
CR (1) CR20180119A (es)
EC (1) ECSP18015616A (es)
ES (1) ES2977953T3 (es)
MX (1) MX386414B (es)
MY (1) MY189306A (es)
PE (1) PE20180605A1 (es)
PH (1) PH12018500236B1 (es)
SG (2) SG11201800591TA (es)
TW (1) TWI710379B (es)
UA (1) UA124663C2 (es)
WO (1) WO2017018473A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11696893B2 (en) 2017-07-10 2023-07-11 Takeda Pharmaceutical Company Limited Preparation comprising vonoprazan

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110538153B (zh) * 2019-09-26 2022-04-26 扬子江药业集团四川海蓉药业有限公司 一种高稳定性、快速释放的固体制剂及其制备方法
UY39094A (es) * 2020-02-27 2021-07-30 Hk Inno N Corp Composición farmacéutica que comprende compuesto derivado de bencimidazol
CN114053239A (zh) * 2020-08-01 2022-02-18 吉林汇康制药有限公司 一种富马酸伏诺拉生药物组合物及制备方法
CA3203701A1 (en) * 2020-12-30 2022-07-07 Min Jung Kim Pharmaceutical composition comprising tegoprazan and non-steroidal anti-inflammatory drugs
CN114762687A (zh) * 2021-01-11 2022-07-19 上海天慈生物谷生物工程有限公司 一种钾离子竞争性酸阻滞剂的预混物及其制备
CN115040491A (zh) * 2021-03-09 2022-09-13 上海天慈生物谷生物工程有限公司 钾离子竞争性酸阻滞剂和乙酰水杨酸的复方制剂及其制备方法
WO2023106841A1 (ko) 2021-12-08 2023-06-15 (주) 팜젠사이언스 벤즈이미다졸 유도체 화합물 및 이의 용도
CN116966180B (zh) * 2022-11-10 2024-05-14 山东道合药业有限公司 沃诺拉赞焦谷氨酸盐的片剂、注射剂、复方制剂
KR20250005906A (ko) 2023-07-03 2025-01-10 주식회사 제뉴원사이언스 보노프라잔푸마르산염을 포함하는 약학 조성물 및 그 제조방법
WO2025064381A1 (en) * 2023-09-18 2025-03-27 Phathom Pharmaceuticals Inc. Method for preparing vonoprazan with reduced nitrosamine
CN118236338B (zh) * 2024-05-29 2024-09-17 寿光富康制药有限公司 一种富马酸伏诺拉生制剂的制备方法
KR20260101702A (ko) * 2024-12-23 2026-06-30 한미약품 주식회사 수불용성 중합체를 이용해 복용 편의성을 개선한 위식도 역류질환 치료제

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
GB9814215D0 (en) 1998-07-01 1998-09-02 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
US20020028240A1 (en) * 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
US8206741B2 (en) * 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
DK1411900T4 (da) 2001-06-01 2014-01-27 Pozen Inc Farmaceutiske sammensætninger til den koordinerede frigørelse af NSAIDs
DE10317023A1 (de) 2003-04-11 2004-11-11 Altana Pharma Ag Perorale Arzneimittelzubereitung für Protonenpumpenantagonisten
TW200503783A (en) 2003-04-11 2005-02-01 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
SA04250092B1 (ar) 2003-05-14 2008-05-04 التانا فاروا ايه جي مركب وسيط جديد لتحضير مركبات إيميدازوبيريدين imidazopyridines فعالة علاجياً
EP1682133A1 (en) 2003-11-03 2006-07-26 AstraZeneca AB Imidazo 1,2-a pyridine derivatives for the treatment of silent gastro-esophageal reflux
EP1718303A4 (en) 2004-02-10 2010-09-01 Santarus Inc COMBINATION OF INHIBITOR OF PROTON PUMP, BUFFER AND NON-STEROIDAL ANTI-INFLAMMATORY DRUG
US20050249799A1 (en) * 2004-03-03 2005-11-10 Spherics, Inc. Polymeric drug delivery system for hydrophobic drugs
AR057181A1 (es) 2005-11-30 2007-11-21 Astra Ab Nueva forma de dosificacion de combinacion
US7776873B2 (en) 2005-12-01 2010-08-17 Yuhan Corporation Method for treating damage to gastric mucosa
WO2007125397A2 (en) 2006-04-27 2007-11-08 Vecta, Ltd. Compositions and methods for inhibiting gastric acidity using endoperoxide bridge-containing compounds
US20090143343A1 (en) 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
CN104784180A (zh) 2008-07-28 2015-07-22 武田药品工业株式会社 药物组合物
NZ591793A (en) 2008-08-27 2012-11-30 Takeda Pharmaceutical Substituted 1-(4-fluoro-5-(2-fluoropyridin-3-yl)-1-((pyrindin-2-yl)sulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine compounds
US20100305163A1 (en) * 2009-05-20 2010-12-02 Pramod Dattatray Yedurkar Pharmaceutical formulations comprising nsaid and proton pump inhibitor drugs
EP2440210A4 (en) 2009-06-12 2014-01-29 Meritage Pharma Inc METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES
JP5787881B2 (ja) 2010-04-30 2015-09-30 武田薬品工業株式会社 腸溶性錠剤
WO2011136376A1 (ja) 2010-04-30 2011-11-03 武田薬品工業株式会社 腸溶性錠剤
CN104080446B (zh) * 2011-11-30 2018-06-29 武田药品工业株式会社 干包衣片
US9539214B2 (en) 2011-12-28 2017-01-10 Pozen Inc. Compositions and methods for delivery of omeprazole plus acetylsalicylic acid
CN105412038A (zh) * 2015-12-11 2016-03-23 北京阜康仁生物制药科技有限公司 一种包含沃诺拉赞和非甾体抗炎药的复方制剂

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11696893B2 (en) 2017-07-10 2023-07-11 Takeda Pharmaceutical Company Limited Preparation comprising vonoprazan

Also Published As

Publication number Publication date
EP3329921A1 (en) 2018-06-06
PE20180605A1 (es) 2018-04-09
CN108135915B (zh) 2021-06-25
MX386414B (es) 2025-03-18
US20180214460A1 (en) 2018-08-02
EP3329921B1 (en) 2024-03-27
EP3329921A4 (en) 2019-03-27
KR102923965B1 (ko) 2026-02-05
CA2994073C (en) 2023-09-05
BR112018001859B1 (pt) 2023-05-02
TWI710379B (zh) 2020-11-21
PH12018500236B1 (en) 2023-12-06
PH12018500236A1 (en) 2018-08-13
MX2018001209A (es) 2018-07-06
TW201714608A (zh) 2017-05-01
CO2018000991A2 (es) 2018-05-10
CA2994073A1 (en) 2017-02-02
HK1249857A1 (en) 2018-11-16
ES2977953T3 (es) 2024-09-03
SG10201914087UA (en) 2020-03-30
MY189306A (en) 2022-02-03
CL2018000246A1 (es) 2018-06-29
WO2017018473A1 (ja) 2017-02-02
UA124663C2 (uk) 2021-10-27
SG11201800591TA (en) 2018-02-27
CN108135915A (zh) 2018-06-08
JPWO2017018473A1 (ja) 2018-05-17
KR20180030412A (ko) 2018-03-22
US10835541B2 (en) 2020-11-17
JP6778680B2 (ja) 2020-11-04
CR20180119A (es) 2018-03-21
BR112018001859A2 (pt) 2018-11-27

Similar Documents

Publication Publication Date Title
CO2018000991A2 (es) Tableta
CR20160192A (es) Formulación de farmaco de liberación retardada
CR20140486A (es) Formulacion de farmaco de liberacion retardada
CL2017003459A1 (es) Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b.
EP3489299A4 (en) LIQUID COMPOSITION AND METHOD FOR PRODUCING A FILM AND LAYER BODY THEREFOR
AR089032A1 (es) Comprimido recubierto seco
EA201490366A1 (ru) Модульная центральная конструкция для совместного запуска космических летательных аппаратов
UY36703A (es) Composiciones y métodos para la administración de un polinucleótido en una planta
CL2016000143A1 (es) Comprimido farmacéutico que comprende ácido acetilsalicílico y clopidogrel
MX2018012800A (es) Administracion de metabolitos de berberina.
CL2015002148A1 (es) Formulaciones farmacéuticas resistentes a la manipulación indebida
AR107029A1 (es) Conexión roscada que incluye un reborde intermedio
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
HUE063831T2 (hu) Eljárás aktivált õssejtek elõállítására, felhasználására és bejuttatására
MX2017005084A (es) Barrera de manchas de laminado y tubo.
AR094371A1 (es) Punzón para fabricación de tubos en caliente
CO2018002428A2 (es) Amida seleccionada de ácido gamma-hidroxiburico y usos de la misma en el tratamiento de abuso de alcohol
CO2018002590A2 (es) Sistemas y métodos para utilizar estructuras biomiméticas que proporcionan comunicación en tejidos vivientes
AR101728A1 (es) Formulación de liberación plurimodal de doxilamina y piridoxina y/o metabolitos o sales de las mismas
PE20181374A1 (es) Formulacion de combinacion farmaceutica
CL2016000529A1 (es) Capa de recubrimiento aislante entre un núcleo que comprende al fármaco y un recubrimiento exterior compuesto por una capa interna y una capa externa, su uso, una formulación de fármaco que contiene a dicha capa aislante, un método para producir a la formulación.
UA102073U (uk) Фармацевтичний препарат на основі сератіопептидази у формі таблеток
TH153153A (th) ยาเม็ดเคลือบแห้ง
BR112016030731A2 (pt) Preparação de compósito, e, método de preparação de uma preparação de compósito
AU366393S (en) A shirt